Lineage Cell Therapeutics/$LCTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Lineage Cell Therapeutics
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
Ticker
$LCTX
Sector
Primary listing
AMEX
Employees
74
Headquarters
Website
LCTX Metrics
BasicAdvanced
$306M
-
-$0.19
1.66
-
Price and volume
Market cap
$306M
Beta
1.66
52-week high
$1.42
52-week low
$0.37
Average daily volume
1.4M
Financial strength
Current ratio
4.076
Quick ratio
3.955
Long term debt to equity
2.348
Total debt to equity
4.572
Profitability
EBITDA (TTM)
-19.768
Gross margin (TTM)
-19.86%
Net profit margin (TTM)
-374.84%
Operating margin (TTM)
-186.87%
Revenue per employee (TTM)
$150,000
Management effectiveness
Return on assets (TTM)
-13.17%
Return on equity (TTM)
-71.51%
Valuation
Price to revenue (TTM)
27.118
Price to book
6.32
Price to tangible book (TTM)
50.89
Price to free cash flow (TTM)
-12.787
Free cash flow yield (TTM)
-7.82%
Free cash flow per share (TTM)
-0.105
Growth
Revenue change (TTM)
76.43%
Earnings per share change (TTM)
37.66%
3-year revenue growth (CAGR)
-6.21%
10-year revenue growth (CAGR)
5.58%
3-year earnings per share growth (CAGR)
-14.84%
10-year earnings per share growth (CAGR)
-9.67%
What the Analysts think about LCTX
Analyst ratings (Buy, Hold, Sell) for Lineage Cell Therapeutics stock.
Bulls say / Bears say
The Phase 1/2a OpRegen trial showed sustained mean BCVA improvement of +6.2 ETDRS letters at 36 months, with as much as +9.0 letters in patients with extensive lesion coverage. These durable results in geographic atrophy secondary to dry AMD highlight the program's potential for future regulatory and commercial milestones. (SEC 8-K)
As of March 31, 2025, Lineage had $47.9 million in cash, cash equivalents, and marketable securities, securing funding into Q1 2027 and materially lowering near-term financing concerns. (Investing.com)
The manufacturing team has completed a cGMP production run for two separate cell therapy candidates sourced from a single pluripotent master cell bank. This demonstrates a platform that can deliver millions of doses and scale across multiple programs. (Nasdaq)
Lineage’s exclusive collaboration with Roche/Genentech for OpRegen involves considerable execution risk; changes in partner priorities or an early termination could delay development and wipe out future milestone and royalty revenues. (SEC 10-K)
Other than OpRegen, Lineage’s pipeline is still mostly at early stages—OPC1 is in Phase 1/2a, and VAC2 is in Phase 1. Setbacks in these programs could leave the company without near-term catalysts. (Nasdaq)
Lineage’s stock has lagged, recording a 26.7% loss over 6 months and down 16.6% year-to-date, reflecting NYSE American’s low liquidity and investor doubts. This may make future equity raises more difficult. (Yahoo Finance)
Data summarised monthly by Lightyear AI. Last updated on 21 Aug 2025.
LCTX Financial Performance
Revenues and expenses
LCTX Earnings Performance
Company profitability
LCTX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lineage Cell Therapeutics stock?
Lineage Cell Therapeutics (LCTX) has a market cap of $306M as of September 13, 2025.
What is the P/E ratio for Lineage Cell Therapeutics stock?
The price to earnings (P/E) ratio for Lineage Cell Therapeutics (LCTX) stock is 0 as of September 13, 2025.
Does Lineage Cell Therapeutics stock pay dividends?
No, Lineage Cell Therapeutics (LCTX) stock does not pay dividends to its shareholders as of September 13, 2025.
When is the next Lineage Cell Therapeutics dividend payment date?
Lineage Cell Therapeutics (LCTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Lineage Cell Therapeutics?
Lineage Cell Therapeutics (LCTX) has a beta rating of 1.66. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.